SLC12A2 and breast cancer: One SD decrease in the SLC12A2 expression was associated with a 17% increase in the risk of ER+BC (1.17, 1.06–1.28), while one SD decrease in PDE1B expression was associated with a 7% decreased risk (0.93, 0.90–0.97).